Prevention and treatment of postmenopausal osteoporosis. - Wikidata - awgldk - TriplyDB

Prevention and treatment of postmenopausal osteoporosis.

Prevention and treatment of postmenopausal osteoporosis.

http://www.wikidata.org/entity/Q34296614

about

Natural Products from Chinese Medicines with Potential Benefits to Bone Health Elevated serum osteoprotegerin levels in women: friend or foe?The role of "bone immunological niche" for a new pathogenetic paradigm of osteoporosis Vitamin D, calcium homeostasis and aging Bone resorption: an actor of dental and periodontal development?Postmenopausal Iron Overload Exacerbated Bone Loss by Promoting the Degradation of Type I Collagen.Effect of low birth weight on women's health.Decreased bone mineral density is associated with coronary atherosclerosis in healthy postmenopausal women.Identification of miR-194-5p as a potential biomarker for postmenopausal osteoporosis.Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics Advanced Oxidation Protein Products as a Novel Marker of Oxidative Stress in Postmenopausal Osteoporosis.Decreased Bone Mineral Density Is an Independent Predictor for the Development of Atherosclerosis: A Systematic Review and Meta-Analysis.Is bone equally responsive to calcium and vitamin D intake from food vs. supplements? Use of (41)calcium tracer kinetic model.Chlorogenic Acid Prevents Osteoporosis by Shp2/PI3K/Akt Pathway in Ovariectomized Rats Akermanite bioceramics promote osteogenesis, angiogenesis and suppress osteoclastogenesis for osteoporotic bone regeneration.A novel pyrazole derivative protects from ovariectomy-induced osteoporosis through the inhibition of NADPH oxidase.Effects of zoledronic acid on bone fusion in osteoporotic patients after lumbar fusion.Adherence to the Mediterranean diet is associated with a higher BMD in middle-aged and elderly Chinese Effects of electroacupuncture at GB points on markers of osteoporosis and bodyweight in ovariectomised rats.Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study.OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.Menopausal Hormone Therapy, Age, and Chronic Diseases: Perspectives on Statistical Trends.Effects of vitamin D deficiency and daily calcium intake on bone mineral density and osteoporosis in Korean postmenopausal woman Effects of strength training on osteogenic differentiation and bone strength in aging female Wistar rats.Osteoprotegerin and kidney disease.Osteoporosis and cardiovascular disease: an update.Evaluating resveratrol as a therapeutic bone agent: preclinical evidence from rat models of osteoporosis.Bazedoxifene and Conjugated Equine Estrogen: A Combination Product for the Management of Vasomotor Symptoms and Osteoporosis Prevention Associated with Menopause.Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis.New Target Sites for Treatment of Osteoporosis.Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care.Osteoporosis and autophagy: What is the relationship?Hydrogen Sulfide and Carbon Monoxide Protect Gastric Mucosa Compromised by Mild Stress Against Alendronate Injury Immune system-related differentially expressed genes, transcription factors and microRNAs in post-menopausal females with osteopenia.INTERTAN nail versus proximal femoral nail antirotation-Asia for intertrochanteric femur fractures in elderly patients with primary osteoporosis.Bone mineral density changes of lumbar spine and femur in osteoporotic patient treated with bisphosphonates and beta-hydroxy-beta-methylbutyrate (HMB): Case report.Lannea acida A. Rich. (Anacardiaceae) Ethanol Extract Exhibits Estrogenic Effects and Prevents Bone Loss in an Ovariectomized Rat Model of Osteoporosis.Effect and mechanism of pyrroloquinoline quinone on anti-osteoporosis in Bmi-1 knockout mice-Anti-oxidant effect of pyrroloquinoline quinone.Peptides and Drug Delivery.Calcitonin alleviates hyperalgesia in osteoporotic rats by modulating serotonin transporter activity.

P2860

Q26765485-6681292A-32B8-434C-851A-375C97E3F025 Q26769686-9E992F17-4E5C-4B95-A5BB-37549B12FF64 Q26780523-D4327FA8-5E34-4A98-A51F-C54B114FE53B Q28073460-FDD23590-7538-4792-A70B-DF3AA7DDBD4A Q28081762-30FDD213-8C85-4036-ACF8-D94858990FB7 Q33768001-36C8C47E-C6B6-4AF7-BF22-51F1BE43A8C1 Q34714425-555DD809-0661-4C49-9A66-8A8613BCB714 Q35198231-0D64AE64-0B1D-4A85-9042-FBBF8CD4AF66 Q35670992-23CD844D-2A2D-4D0E-AE65-DCF1226E6250 Q35792875-94E53A06-510F-4F54-A27C-8AC03CE8C3C4 Q35990746-2AF7C485-9C11-4D51-8295-9950F388E8F3 Q36009417-DA8C6F76-2301-424F-A5B3-96B671D28192 Q36067391-A9F604D9-1DA5-4EA0-9195-798A13F5CE98 Q36235538-CBF97C8C-09FE-4FC8-A70C-57FBA9E3AC88 Q36615858-2C2E8C3E-6302-4C27-9D0B-1B55E8C94191 Q36687909-5D6708DF-1D72-4037-87B1-48C45EDE20F4 Q36689300-9303A5BC-2AA0-4816-8314-59DAC6F58F9E Q36882274-ACA1917F-4A32-4BA1-9C53-2C2634C7E922 Q36883204-3654971C-73D3-40B0-A582-4DB69C6206CF Q36935525-5A2E88C8-4667-4EFD-87DB-D1D5EAE09099 Q37199204-EB7393F5-CD9E-42D9-8A94-1569D91D7998 Q37349131-9A9DAC3D-CA25-4BB4-85A0-D35CBE240B0B Q37647334-60F0C8EF-DC86-4483-9AFB-03A1AB4BE42B Q37648796-DC78AD2B-3BBE-4F1B-BB43-4E7F3958A014 Q38206487-FD41AD70-0BEF-408E-957F-09FB3D51FF46 Q38513410-A703E672-C792-4312-8E6B-801BDF74C072 Q38551935-4D406F9C-9CE5-4CBC-888E-F293D9CD61B1 Q38793387-AE9943DD-A6B0-43D8-8CB7-951CAD254AC7 Q38806177-E7ED39C3-4DA2-4DB9-B182-DD9EED1ABC77 Q39151180-D0A2AB88-4E69-4C66-B420-F6BC874BABE9 Q39179797-B73F2B71-BF87-41D4-99B7-7B6A9DB97855 Q39206865-1397E23D-ED3C-4302-8356-83A97DCD389C Q41481543-8566BF63-F065-48C8-9055-8EFBE1EBD580 Q41614826-52713943-D3D1-477E-B049-2114015E48EA Q42284982-2B4BCDF9-12DC-4BD7-808C-3F18EBD31802 Q45331855-6A8E2C0B-B73F-47E4-BDA3-7719E65F921A Q47145174-92F5BCCE-B6DD-4916-8A6C-D4380ADB14A0 Q47162342-C31A191B-082D-4966-BF90-162E457FF75F Q47590591-1EFD2775-D46E-49B2-8459-85329E46D076 Q48053382-E1A4D05E-3B9B-40F6-81FF-88E0624E3730

P2860

Prevention and treatment of postmenopausal osteoporosis.

http://www.wikidata.org/entity/Q34296614

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Prevention and treatment of postmenopausal osteoporosis.

@ast

Prevention and treatment of postmenopausal osteoporosis.

@en

Prevention and treatment of postmenopausal osteoporosis.

@nl

type

label

Prevention and treatment of postmenopausal osteoporosis.

@ast

Prevention and treatment of postmenopausal osteoporosis.

@en

Prevention and treatment of postmenopausal osteoporosis.

@nl

prefLabel

Prevention and treatment of postmenopausal osteoporosis.

@ast

Prevention and treatment of postmenopausal osteoporosis.

@en

Prevention and treatment of postmenopausal osteoporosis.

@nl

P1433

Q34296614-97F42F1B-B259-4549-B13F-5C7184295500

P1476

Q34296614-2811D440-E633-4971-9C5A-F382272C9972

P2093

Q34296614-550CAAC3-B69B-40AA-B439-48667EAF87E8

Q34296614-D843BDB2-7F84-417D-ABC3-F739EC7D6FFA

P2860

Q34296614-0814DBA0-EF5E-419F-BA33-E3A7D0B3113F

Q34296614-0849133D-58EE-430F-9FB3-3024DD2C8980

Q34296614-0BE5F30B-E947-4B2B-A2E2-E64D44034AA4

Q34296614-109216AF-C025-4AC3-B878-30A76E85ED2F

Q34296614-167FF1CC-B2EF-4619-9F02-2099FC91FBBF

Q34296614-1AB02F16-361E-446D-AAD9-703F3B233B70

Q34296614-1CB311CF-453C-48B6-B834-CAA70353B8B3

Q34296614-22784AD7-7DEB-4A76-B219-2376127CB380

Q34296614-23D7533C-704F-44DB-A5AB-F9C7314CC108

Q34296614-24AEFB43-ECE3-4656-947C-1885F3B82A74

P304

Q34296614-73689113-6704-427A-B9BB-5CCA16F19006

P31

Q34296614-C6CE11E8-A824-413A-AED1-74D1A0006167

P356

Q34296614-820A455D-22DE-406D-A30A-29F7D9414B78

P478

Q34296614-EC161969-F443-400D-9279-7094A7833E7C

P577

Q34296614-4761F92D-6538-439D-9ED7-FE4DEC73B4FF

P698

Q34296614-0733A3DB-4AFB-4D31-AC57-6E8A13C7A7A1

P921

Q34296614-119C0C93-A63C-4877-A8E8-D1892897340A

P932

Q34296614-29875640-5B58-4DD0-95B2-3C7C03CE4BCE

P356

J.JSBMB.2013.09.008

P1433

The Journal of Steroid Biochemistry and Molecular Biology

P1476

Prevention and treatment of postmenopausal osteoporosis.

@en

P2093

J Christopher Gallagher

http://www.w3.org/2001/XMLSchema#string

Sri Harsha Tella

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis

Vitamin D deficiency

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

Lasofoxifene in postmenopausal women with osteoporosis

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.

P304

155-170

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JSBMB.2013.09.008

http://www.w3.org/2001/XMLSchema#string

P478

142

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24176761

http://www.w3.org/2001/XMLSchema#string

P921

P932

4187361

http://www.w3.org/2001/XMLSchema#string